US8871759 — Inhibitors of hepatitis C virus replication
Method of Use · Assigned to Merck Sharp and Dohme LLC · Expires 2031-05-04 · 5y remaining
What this patent protects
This patent protects compounds that inhibit hepatitis C virus replication and are useful for treating or preventing HCV infections.
USPTO Abstract
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Drugs covered by this patent
- Zepatier (ELBASVIR) · Merck & Co.
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1813 |
— | Zepatier |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.